Pharmaceuticals Global On demand · 24-48h

Global Cardiovascular and Cerebrovascular API Market Strategic Research Report

Global Cardiovascular and Cerebrovascular API Market Strateg…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Cardiovascular and Cerebrovascular API Market
$3.41B2025
2.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Sartans Cardiovascular and Cerebrovascular API, Statins Cardiovascular and Cerebrovascular API, Puri Cardiovascular and Cerebrovascular API

By Application: Oral Drugs, Injection Drugs

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Zhuhai Rundu Pharmaceutical, Ningbo Menovo Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zhejiang Tianyu Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Lepu Pharmaceutical, Zhejiang Jiangbei Pharmaceutical, DR.Reddy, Glenmerk, Cipla, MSN Life Sciences

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 113 pages
Market size 2025
$3.41B
Billion USD
Forecast CAGR
2.6%
2025-2032
Forecast 2032
$4.1B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

Scope of the Report

The global Cardiovascular and Cerebrovascular API market size is predicted to grow from US$ 3,414 million in 2025 to US$ 4,088 million in 2032; it is expected to grow at a CAGR of 2.6% from 2026 to 2032.

Cardiovascular disease (CVD) is the leading cause of death in the world. The number of people who die of cardiovascular disease is the largest every year. Cardiovascular drugs are used to treat cardiovascular diseases, including antihypertensive drugs, anti angina drugs, anti heart failure drugs, antiarrhythmic drugs, lipid-lowering drugs and so on. The main raw materials of cardio cerebrovascular drugs include sartan, statins, pril and so on.

China is the main production area of cardiovascular and cerebrovascular raw materials, with a market share of more than 65%, followed by India and Europe.

The key manufacturers are Zhuhai Rundu Pharmaceutical, Ningbo Menovo Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zhejiang Tianyu Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Lepu Pharmaceutical, Zhejiang Jiangbei Pharmaceutical, DR.Reddy, Glenmerk, Cipla, MSN Life Sciences etc. Zhejiang Huahai Pharmaceutical Co., Ltd. is the largest producer of cardiovascular and cerebrovascular raw materials in China region market and global market, accounting for more than 10%.

This report presents a comprehensive overview of the global Cardiovascular and Cerebrovascular API market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Sartans Cardiovascular and Cerebrovascular API
  • Statins Cardiovascular and Cerebrovascular API
  • Puri Cardiovascular and Cerebrovascular API

Segment by Application

  • Oral Drugs
  • Injection Drugs

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cardiovascular and Cerebrovascular API market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Oral Drugs, Injection Drugs evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Cardiovascular and Cerebrovascular API Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 2.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$3.41B
2025
Forecast
$4.1B
2032
CAGR
2.6%
2025–2032
Regions
5
global
Key companies
Zhuhai Rundu PharmaceuticalNingbo Menovo PharmaceuticalZhejiang Huahai PharmaceuticalZhejiang Tianyu PharmaceuticalZhejiang Hisun PharmaceuticalZhejiang Lepu PharmaceuticalZhejiang Jiangbei PharmaceuticalDR.Reddy
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Sartans Cardiovascular and Cerebrovascular APIStatins Cardiovascular and Cerebrovascular APIPuri Cardiovascular and Cerebrovascular API
By Application
Oral DrugsInjection Drugs

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Sartans Cardiovascular and Cerebrovascular API
  • 3.1.3 Statins Cardiovascular and Cerebrovascular API
  • 3.1.4 Puri Cardiovascular and Cerebrovascular API
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Oral Drugs
  • 4.1.3 Injection Drugs
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Zhuhai Rundu Pharmaceutical
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Ningbo Menovo Pharmaceutical
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Zhejiang Huahai Pharmaceutical
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Zhejiang Tianyu Pharmaceutical
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Zhejiang Hisun Pharmaceutical
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Zhejiang Lepu Pharmaceutical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Zhejiang Jiangbei Pharmaceutical
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 DR.Reddy
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Glenmerk
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Cipla
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 MSN Life Sciences
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Cardiovascular and Cerebrovascular API market?
The global Cardiovascular and Cerebrovascular API market is estimated at US$ 3.41 billion in 2025 (base year) and is projected to reach US$ 4.09 billion by 2032.
What is the forecast CAGR for the Cardiovascular and Cerebrovascular API market?
The market is expected to grow at a CAGR of 2.6% from 2026 to 2032, expanding from US$ 3.41 billion in 2025 to US$ 4.09 billion in 2032, roughly 1.2 times its base-year value.
What is Cardiovascular and Cerebrovascular API?
Cardiovascular disease (CVD) is the leading cause of death in the world. The number of people who die of cardiovascular disease is the largest every year. Cardiovascular drugs are used to treat cardiovascular diseases, including antihypertensive drugs, anti angina drugs, anti heart failure drugs, antiarrhythmic drugs, lipid-lowering drugs and so on.
What are the main segments of the Cardiovascular and Cerebrovascular API market by type?
By type, the market is segmented into Sartans Cardiovascular and Cerebrovascular API, Statins Cardiovascular and Cerebrovascular API and Puri Cardiovascular and Cerebrovascular API.
Which applications drive demand in the Cardiovascular and Cerebrovascular API market?
Key applications covered include Oral Drugs and Injection Drugs.
Who are the key players in the Cardiovascular and Cerebrovascular API market?
Key players profiled include Zhuhai Rundu Pharmaceutical, Ningbo Menovo Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zhejiang Tianyu Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Lepu Pharmaceutical, Zhejiang Jiangbei Pharmaceutical and DR.Reddy, among 11 companies covered in total.
Which regions and countries are covered for Cardiovascular and Cerebrovascular API?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Cardiovascular and Cerebrovascular API market report?
The report is intended for manufacturers and solution providers, distributors and end users in Oral Drugs and Injection Drugs, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Cardiovascular and Cerebrovascular API market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from ‏3,500.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.